A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata

References

• Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic jak inhibitors in dermatology. Front Immunol. 2019;10:2847. doi:10.3389/fimmu.2019.02847
   PubMed Web of Science ®Google Scholar
• Johnson R, Roh E, Saavedra A, Wolff K. Fitzpatrick’s Colour Atlas and Synopsis of Clinical Dermatology. 8th ed. New York: McGraw-Hill Edu; 2017.
   Google Scholar
• Oakley A. Alopecia Areata. DermNet NZ; 2015. Available from: https://dermnetnz.org/topics/alopecia-areata/. Accessed February 3, 2020.
   Google Scholar
• Trueb R, Dutra H, Dias M. A comment on jak inhibitors for treatment of alopecia areata. Int J Trichology. 2018;10(5):193–197. doi:10.4103/ijt.ijt_62_18
   Google Scholar
• Damsky W, King B. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744. doi:10.1016/j.jaad.2016.12.005
   PubMed Web of Science ®Google Scholar
• Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Develop Ther. 2018;12:2323–2335. doi:10.2147/DDDT.S172638
   PubMed Web of Science ®Google Scholar
• Guo H, Cheng Y, Shapiro J, McElwee K. The role of lymphocytes in the development and treatment of alopecia areata. Expert Rev Clin Immunol. 2015;11(12):1335–1351. doi:10.1586/1744666X.2015.1085306
   PubMed Web of Science ®Google Scholar
• Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. J Invest Dermatol Symposium Proceedings. 2003;8(2):188–194. doi:10.1046/j.1087-0024.2003.00807.x
   PubMed Web of Science ®Google Scholar
• Kranseler J, Sidbury R. Alopecia areata: update on management. Indian J Paediatr Dermatol. 2017;18(4):261–266. doi:10.4103/ijpd.IJPD_80_17
   Google Scholar
• Anzai A, Wang E, Lee E, Aoki V, Christiano A. Pathomechanisms of immune-mediated alopecia. Int Immunol. 2019;31(7):439–447. doi:10.1093/intimm/dxz039
   Web of Science ®Google Scholar
• D’Ovidio R. Alopecia areata: news on diagnosis, pathogenesis and treatment. G Ital Dermatol Venereol. 2014;149(1):25–45.
   PubMed Web of Science ®Google Scholar
• Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by jak inhibition. Nat Med. 2014;20(9):1043–1049. doi:10.1038/nm.3645
   PubMed Web of Science ®Google Scholar
• McElwee K, Freyschmidt-Paul P, Hoffman R, et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/Cd25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol. 2005;124(5):947–957. doi:10.1111/j.0022-202X.2005.23692.x
   PubMed Web of Science ®Google Scholar
• Trueb R, Dias M. Alopecia areata: a comprehensive review of pathogenesis and management. Clin Rev Allergy Immunol. 2017;54:68–87. doi:10.1007/s12016-017-8620-9
   Web of Science ®Google Scholar
• Darwin E, Hirt P, Fertig R, Doliner B, Delcanto G, Jimenez J. Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichology. 2018;10(2):51–60. doi:10.4103/ijt.ijt_99_17
   PubMedGoogle Scholar
• Petukhova L, Christiano A. Functional interpretation of genome-wide association study evidence in alopecia areata. J Invest Dermatol. 2016;136(1):314–317. doi:10.1038/JID.2015.402
   PubMed Web of Science ®Google Scholar
• Betz R, Petukhova L, Ripke S, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. 2015;6:5966. doi:10.1038/ncomms6966
   PubMed Web of Science ®Google Scholar
• Manolache L, Benea V. Stress in patients with alopecia areata and vitiligo. J Eur Acad Dermatol Venereol. 2007;21(7):921–928. doi:10.1111/j.1468-3083.2006.02106.x
   Web of Science ®Google Scholar
• Gulec T, Tanriverdi N, Duru C, Saray Y, Akcali C. The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol. 2004;43(5):352–356. doi:10.1111/j.1365-4632.2004.02028.x
   Web of Science ®Google Scholar
• Habif T. Clinical Dermatology. A Guide to Diagnosis and Therapy. 6th ed. Netherlands: Elsevier Inc; 2016.
   Google Scholar
• Korta D, Christiano A, Berfield W, et al. Alopecia areata is a medical disease. J Am Acad Dermatol. 2018;78(4):832–834. doi:10.1016/j.jaad.2017.09.011
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Ayoobzadehshirazi A. A review of psychiatric disorders comorbidities in patients with alopecia areata. Int J Trichology. 2014;6(1):2–4. doi:10.4103/0974-7753.136746
   PubMedGoogle Scholar
• Fricke A, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397–403. doi:10.2147/CCID.S53985
   PubMedGoogle Scholar
• Delamere FM, Sladden MJ, Dobbins HM, Leonardi-Bee J, Macbeth A. Interventions for alopecia areata. Cochrane Database of Systematic Reviews. 2008;CD004413. doi:10.1002/14651858.CD004413.pub2
   Web of Science ®Google Scholar
• Hammerschmidt M, Brenner F. Efficacy and safety of methotrexate in alopecia areata. An Bras Dermatol. 2014;89(5):729–734. doi:10.1590/abd1806-4841.20142869
   PubMed Web of Science ®Google Scholar
• Vano-Galvan S, Hermosa-Gelbard A, Sanchez-Neila N, et al. Treatment of Recalcitrant Adult Alopecia Areata Universalis with Oral Azathioprine. J Am Acad Dermatol. 2016;74(5):1007–1008. doi:10.1016/j.jaad.2015.12.055
   Web of Science ®Google Scholar
• Wang E, Sallee B, Tejeda C, Christiano A. Montagna symposium 2017- janus kinase inhibitors for treatment of alopecia areata. J Invest Dermatol. 2018;138(9):1911–1966. doi:10.1016/j.jid.2018.05.027
   Web of Science ®Google Scholar
• Fragoulis G, McInnes I, Siebert S. JAK-inhibitors: new players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology. 2019;58(1):43–54. doi:10.1093/rheumatology/key276
   Web of Science ®Google Scholar
• Aittomaki S, Pesu M. Therapeutic targeting of the JAK/STAT pathway. Basic Clin Pharmacol Toxicol. 2013;114(1):18–23. doi:10.1111/bcpt.12164
   Web of Science ®Google Scholar
• O’Shea J, Plenge R. JAKs and STATs in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542–550. doi:10.1016/j.immuni.2012.03.014
   PubMed Web of Science ®Google Scholar
• Renert-Yuval Y, Guttman-Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther. 2017;34:1594–1609. doi:10.1007/s12325-017-0542-7
   PubMed Web of Science ®Google Scholar
• Craiglow B, King B. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988–2990. doi:10.1038/jid.2014.260
   PubMed Web of Science ®Google Scholar
• Anzengruber F, Maul J, Kamarachev J, Trueb R, French L, Navarini A. Transient efficacy of tofacitinib in alopecia areata universalis. Case Rep Dermatol. 2016;8(1):102–106. doi:10.1159/000445182
   PubMed Web of Science ®Google Scholar
• Dhayalan A, King B. Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA. 2016;152(4):492–493.
   Google Scholar
• Ferreira S, Scheinberg M, Steiner D, Steiner T, Bedin G, Ferreira R. Remarkable improvement of nail changes in alopecia areata universalis with 10 months of treatment with tofacitinib: a case report. Case Rep Dermatol. 2016;8(3):262–266. doi:10.1159/000450848
   PubMed Web of Science ®Google Scholar
• Gupta A, Carviel J, Abramovits W. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatol Venereol. 2016;30(8):1373–1378. doi:10.1111/jdv.13598
   PubMed Web of Science ®Google Scholar
• Jabbari A, Nguyen N, Cerise J, et al. Treatment of alopecia areata with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol. 2016;25(8):642–643. doi:10.1111/exd.13060
   PubMed Web of Science ®Google Scholar
• Kennedy Crispin M, Ko J, Craiglow B, et al. Safety and efficacy of the jak inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776. doi:10.1172/jci.insight.89776
   PubMed Web of Science ®Google Scholar
• Bayart C, DeNiro K, Brichta L, Craiglow B, Sidbury R. Topical janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017;77(1):167–170. doi:10.1016/j.jaad.2017.03.024
   PubMed Web of Science ®Google Scholar
• Castelo-Soccio L. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. J Am Acad Dermatol. 2017;76(4):754–755. doi:10.1016/j.jaad.2016.11.038
   PubMed Web of Science ®Google Scholar
• Craiglow B, Liu L, King B. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76(1):29–32. doi:10.1016/j.jaad.2016.09.006
   PubMed Web of Science ®Google Scholar
• Erduran F, Adisen E, Aksakal A. Excellent response to tofacitinib in a patient with alopecia universalis. Acta Dermatovenerol APA. 2017;26:47–49. doi:10.15570/actaapa.2017.15
   Web of Science ®Google Scholar
• Ibrahim O, Bayart C, Hogan S, Piliang M, Bergfeld W. Treatment of alopecia areata with tofacitinib. JAMA. 2017;153(6):600–602.
   Google Scholar
• Kim B, Kim H. Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment. Singapore Med J. 2017;58(5):279–280. doi:10.11622/smedj.2017039
   PubMed Web of Science ®Google Scholar
• Liu L, Craiglow B, King B, Dai F. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22–28. doi:10.1016/j.jaad.2016.09.007
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Gerdes S, Glaser R, Schroder O. Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman. Acta Derm Venereol. 2017;97(2):283–284. doi:10.2340/00015555-2491
   PubMed Web of Science ®Google Scholar
• Park H, Kim M, Lee J, Huh C, Kwon O, Cho S. Oral tofacitinib monotherapy in Korean patients with refractory moderate-severe alopecia areata: a Case Series. J Am Acad Dermatol. 2017;77(5):978–980. doi:10.1016/j.jaad.2017.06.027
   PubMed Web of Science ®Google Scholar
• Salman A, Sarac G, Ergun T. Alopecia universalis unresponsive to treatment with tofacitinib: report of a case with brief review of the literature. Dermatol Online J. 2017;23(7):15.
   Google Scholar
• Scheinberg M, de Lucena Couto Océa RA, Cruz BA, Ferreira SB. Brazilian experience of the treatment of alopecia universalis with the novel antirheumatic therapy tofacitinib: a case series. Rheumatol Ther. 2017;4(2):503–508. doi:10.1007/s40744-017-0069-z
   PubMed Web of Science ®Google Scholar
• Strazzulla LC, Avila L, Sicco K, Shapiro J. Image Gallery: treatment of refractory alopecia universalis with oral tofacitinib citrate and adjunct intralesional triamcinolone injections. Br J Dermatol. 2017;176(6):e125. doi:10.1111/bjd.15483
   Web of Science ®Google Scholar
• Jabbari A, Sansarcq F, Cerise J, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch type alopecia areata, totalis and universalis. J Invest Dermatol. 2018;138(7):1539–1545. doi:10.1016/j.jid.2018.01.032
   PubMed Web of Science ®Google Scholar
• Liu L, Craiglow B, King B. Tofacitinib 2% ointment, a topical janus kinase inhibitor for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol. 2018;78(2):403–404. doi:10.1016/j.jaad.2017.10.043
   PubMed Web of Science ®Google Scholar
• Patel N, Oussedik E, Grammenos A, Pichardo-Geisinger R. A case report highlighting the effective treatment of alopecia universalis with tofacitinib in an adolescent and adult patient. J Cutan Med Surg. 2018;22(4):439–442. doi:10.1177/1203475418760512
   PubMed Web of Science ®Google Scholar
• Shivanna C, Shenoy C, Priya R. Tofacitinib (selective janus kinase inhibitor 1 and 3): a promising therapy for the treatment of alopecia areata: a case report of six patients. Int J Trichology. 2018;10(3):103–107. doi:10.4103/ijt.ijt_21_18
   PubMedGoogle Scholar
• Akdogan N, Ersoy-Evans S, Dogan S, Atakan N. Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata. Dermatol Ther. 2019;32(6):e13118. doi:10.1111/dth.13118
   Web of Science ®Google Scholar
• Ferreira S, Ferreira R, Scheinberg M. An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: a case report and a review of the literature. Clin Case Rep. 2019;7(12):2539–2542. doi:10.1002/ccr3.2484
   Web of Science ®Google Scholar
• Jerjen R, Meah N, Trindade de Carvalho L, Wall D, Eisman S, Sinclair R. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: a retrospective study. Pediatr Dermatol. 2021;38(1):103–108. doi:10.1111/pde.14422
   PubMed Web of Science ®Google Scholar
• Dincer Rota D, Emeksiz MAC, Erdogan FG, Yildirim D. Experience with oral tofacitinib in severe alopecia areata with different clinical responses. J Cosmet Dermatol. 2021;00:1–8.
   Google Scholar
• Higgins E, Al Shehri T, McAleer M, Feighery C, Lilic D, Irvine A. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis cause by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015;135(2):551–553. doi:10.1016/j.jaci.2014.12.1867
   PubMed Web of Science ®Google Scholar
• Pieri L, Guglielmelli P, Vannucchi A. Roxulitinib-induced reversal of alopecia universalis in a patient with essential thrombocytopenia. Am J Hematol. 2015;90(1):82–83. doi:10.1002/ajh.23871
   PubMed Web of Science ®Google Scholar
• Craiglow B, Tavares D, King B. Topical ruxolitinib for the treatment of alopecia universalis. JAMA. 2016;152(4):490–491.
   Google Scholar
• Harris J, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata. J Am Acad Dermatol. 2016;74(2):370–371. doi:10.1016/j.jaad.2015.09.073
   PubMed Web of Science ®Google Scholar
• Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair-growth in patients with moderate-severe alopecia areata. JCI Insight. 2016;1(15):e89790. doi:10.1172/jci.insight.89790
   PubMed Web of Science ®Google Scholar
• Deeb M, Beach R. A case of topical ruxolitinib treatment failure in alopecia areata. J Cutan Med Surg. 2017;21(6):562–563. doi:10.1177/1203475417716363
   PubMed Web of Science ®Google Scholar
• Vandiver A, Girardi N, Alhariri J, Garza L. Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring. Int J Dermatol. 2017;56(8):833–835. doi:10.1111/ijd.13598
   PubMed Web of Science ®Google Scholar
• Ramot Y, Zlotogorski A. Complete regrowth of beard with roxulitinib in an alopecia universalis patient. Skin Appendage Disord. 2018;4(2):122–124. doi:10.1159/000479722
   PubMed Web of Science ®Google Scholar
• Liu L, King B. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol. 2019;80(2):566–568. doi:10.1016/j.jaad.2018.08.040
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kornacki D, Sun K, Hordinsky MK. Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled Phase 2 study. J Am Acad Dermatol. 2020;82(2):412–419. doi:10.1016/j.jaad.2019.10.016
   PubMed Web of Science ®Google Scholar
• Fetter T, Cuevas Rios G, Niebel D, Bieber T, Wenzel J. Unexpected hair regrowth in a patient with longstanding alopecia universalis during treatment of recalcitrant dermatomyositis with the janus kinase inhibitor ruxolitinib. Acta Derm Venereol. 2020;100(10):adv00144. doi:10.2340/00015555-3481
   Google Scholar
• Peterson D, Vesely M. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient. J Am Acad Dermatol. 2020;6(4):257–259.
   Google Scholar
• Jabbari A, Zhenpeng D, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine. 2015;2(4):351–355. doi:10.1016/j.ebiom.2015.02.015
   PubMed Web of Science ®Google Scholar
• Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib. J Am Acad Dermatol. 2019;5(10):892–894.
   Google Scholar
• Shi J, Chen X, McGee R, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51(12):1644–1654. doi:10.1177/0091270010389469
   PubMed Web of Science ®Google Scholar
• Carfagna M, Cannady E, Ryan T, et al. Carcinogenicity assessment of baricitinib in Tg.rasH2 mice and Sprague-Dawley (Crl: CD)rats. Regul Toxicol Pharmacol. 2018;92:458–471. doi:10.1016/j.yrtph.2017.11.020
   Web of Science ®Google Scholar
• Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850–856. doi:10.1111/jdv.15489
   PubMed Web of Science ®Google Scholar
• Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(1):192–201. doi:10.1111/jdv.15937
   PubMed Web of Science ®Google Scholar
• Gilhar A, Keren A, Paus R. JAK inhibitors and alopecia areata. The Lancet. 2019;393(10169):318–319. doi:10.1016/S0140-6736(18)32987-8
   Web of Science ®Google Scholar
• GlobalData Healthcare. Can JAK inhibitors penetrate the alopecia areata market effectively. GlobalData Healthcare, Pharmaceutical Technology; 2019. Available from: https://www.pharmaceutical-technology.com/comment/alopecia-areata-treatment-2019/#:~:text=Primary%20research%20conducted%20by%20GlobalData,inhibitor%20is%20just%20under%20%241%2C400. Accessed June 19, 2020.
   Google Scholar
• Xconomy. With FDA’s Eye on JAK Drugs, Concert Pharma Moves One Ahead for Hair Loss; 2019. Available from: https://xconomy.com/boston/2019/09/03/with-fdas-eye-on-jak-drugs-concert-pharma-moves-one-ahead-for-hair-loss/. Accessed June 19, 2020.
   Google Scholar